Dutasteride/Tamsulosin Diagonalis 0.5mg/0.4mg hard capsules

Država: Malta

Jezik: engleski

Izvor: Malta Medicines Authority

Aktivni sastojci:

DUTASTERIDE, TAMSULOSIN HYDROCHLORIDE

Dostupno od:

Galenicum Health, S.L.

ATC koda:

G04CA52

INN (International ime):

DUTASTERIDE, TAMSULOSIN HYDROCHLORIDE

Farmaceutski oblik:

HARD CAPSULE

Sastav:

DUTASTERIDE 0.5 milligram(s) ; TAMSULOSIN HYDROCHLORIDE 0.4 milligram(s)

Tip recepta:

POM

Područje terapije:

UROLOGICALS

Status autorizacije:

Authorised

Datum autorizacije:

2019-09-06

Uputa o lijeku

Page
1
of
8
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DUTASTERIDE/TAMSULOSIN DIAGONALIS 0.5MG/0.4 MG HARD CAPSULES
dutasteride/tamsulosin hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dutasteride/Tamsulosin Diagonalis is and what it is used for
2.
What you need to know before you take Dutasteride/Tamsulosin
Diagonalis
3.
How to take Dutasteride/Tamsulosin Diagonalis
4.
Possible side effects
5.
How to store Dutasteride/Tamsulosin Diagonalis
6.
Contents of the pack and other information
1.
WHAT DUTASTERIDE/TAMSULOSIN DIAGONALIS IS AND WHAT IT IS USED FOR
DUTASTERIDE/TAMSULOSIN DIAGONALIS IS USED TO TREAT MEN WITH AN
ENLARGED PROSTATE
(
_benign _
_prostatic hyperplasia_
) - a non-cancerous growth of the prostate gland, caused by producing
too
much of a hormone called dihydrotestosterone.
Dutasteride/Tamsulosin Diagonalis is a combination of two different
medicines called dutasteride
and tamsulosin.
Dutasteride belongs to a group of medicines called
_5-alpha reductase inhibitors_
and tamsulosin
belongs to a group of medicines called
_alpha-blockers_
.
As the prostate grows, it can lead to urinary problems, such as
difficulty in passing urine and a need
to go to the toilet frequently. It can also cause the flow of the
urine to be slower and less forceful. If
left untreated, there is a risk that your urine flow will be
completely blocked (
_acute urinary _
_retention_
). This requires immediate medical treatment. Sometimes surgery is
necessary to remove or
reduce the size of the pro

Svojstava lijeka

1
1.
NAME OF THE MEDICINAL PRODUCT
Dutasteride/Tamsulosin Diagonalis 0.5mg/0.4mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains 0.5 mg dutasteride and 0.4 mg tamsulosin
hydrochloride (equivalent to
0.367 mg tamsulosin).
Excipients with known effect
Each capsule contains lecithin (which may contain soya oil) and sunset
yellow FCF (E 110). Each
capsule contains ≤ 0.1 mg sunset yellow FCF.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule
Oblong, around 24 mm length, hard capsules with a brown body and an
orange cap.
Each hard capsule contains tamsulosin hydrochloride modified release
pellets and one dutasteride
soft gelatin capsule.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of moderate to severe symptoms of benign prostatic
hyperplasia (BPH).
Reduction in the risk of acute urinary retention (AUR) and surgery in
patients with moderate to
severe symptoms of BPH.
For information on effects of treatment and patient populations
studied in clinical trials please see
section 5.1.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults (including elderly) _
The
recommended
dose
of
Dutasteride/Tamsulosin
Diagonalis
is
one
capsule
(0.5 mg/ 0.4mg) once daily.
Where appropriate, Dutasteride/Tamsulosin Diagonalis may be used to
substitute concomitant
dutasteride and tamsulosin hydrochloride in existing dual therapy to
simplify treatment.
Page
2
of
21
Where
clinically
appropriate,
direct
change
from
dutasteride
or
tamsulosin
hydrochloride
monotherapy to Dutasteride/Tamsulosin Diagonalis may be considered.
_Renal impairment _
The effect of renal impairment on dutasteride-tamsulosin
pharmacokinetics has not been studied.
No adjustment in dosage is anticipated for patients with renal
impairment (see section 4.4 and 5.2).
_ _
_Hepatic impairment _
The effect of hepatic impairment on dutasteride-tamsulosin
pharmacokinetics has not been studied
so caution should be used in patients with mild to moderate hepatic
impairment (see sectio